ONL Therapeutics announced the randomization of the first patient in its global Phase 2 GALAXY clinical trial evaluating Xelafaslatide (ONL1204) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). According to the company, the milestone marks a key step in advancing its neuroprotective therapy designed to preserve retinal cells and slow disease progression.
The company said that the GALAXY trial is a randomized, double-masked, placebo-controlled study aimed at assessing the safety and efficacy of Xelafaslatide. The therapy is intended to block the activity of a specific protein that contributes to photoreceptor cell death, which is a major cause of vision loss in GA.
ONL Therapeutics stated that the trial will enroll participants across multiple countries and will evaluate both functional and structural endpoints to determine treatment impact. According to the company, Xelafaslatide has previously demonstrated safety and biological activity in earlier-stage clinical studies.
The company claims that the launch of this Phase 2 study represents progress in developing a novel class of neuroprotective treatments for degenerative retinal diseases. ONL Therapeutics said that it remains focused on advancing its pipeline of therapies designed to protect vision by targeting cell survival pathways.
